  Abbreviations, acronyms & symbols                                               
  ----------------------------------- -------------------------------- --- ------ -----------------------------------------
  2D                                  = Two-dimensional                    OR     = Odds ratio
  AF                                  = Atrial fibrillation                PAF    = Paroxysmal atrial fibrillation
  BMI                                 = Body mass index                    RAAS    = Renin-angiotensin-aldosterone system
  CAD                                 = Coronary artery disease            SPSS   = Lactate dehydrogenase
  CV                                  = Cardioversion                      TEE    = Transesophageal echocardiography
  DM                                  = Creatine kinase-muscle/brain       TSH    = Thyroid-stimulating hormone
  ECG                                 = Electrocardiography                TSH    = Thyroid-stimulating hormone
  ECG                                 = Electrocardiography                VitD   = Vitamin D
  HT                                  = Hypertension                               

INTRODUCTION
============

Atrial fibrillation (AF) is the most common chronic arrhythmia in the elderly population and associated with increased risk of stroke, high morbidity and mortality^\[[@r1],[@r2]\]^. Although there are several risk factors for AF, such as hypertension (HT), diabetes mellitus (DM), heart failure (HF), older age, coronary artery disease (CAD), valvular heart disease and obesity, the aetiology of AF is still largely unknown^\[[@r3],[@r4]\]^. Medical and electrical cardioversion (CV) are well-established treatment modalities to restore sinus rhythm in patients with AF^\[[@r5]\]^. Several factors, including type of AF, patient comorbidities, structural heart disease, and anticoagulation status, should be considered deciding to perform CV^\[[@r6]\]^.

Restoration and maintenance of sinus rhythm improve quality of life in symptomatic patients. The procedural success of CV depends on age, AF duration, left atrial size, CAD and chronic pulmonary disease^\[[@r7],[@r8]\]^. Smoking, CAD, sleep apnea syndromes and type of AF are associated with increased risk of AF recurrence^\[[@r9]\]^.

Vitamin D (vitD) is transformed into an active metabolite in kidney and liver and binds specific tissue receptors on intestines, bone and kidney to increase serum calcium level. VitD receptors are also found in cardiomyocytes, brain, vascular smooth muscle cells, endothelial cells, pancreas, prostate and skeletal muscles^\[[@r10]\]^. In recent years, vitD deficiency has been shown not only to increase the risk of skeletal system diseases, but also to have adverse effects on the cardiovascular system with regulating the renin-angiotensin-aldosterone system (RAAS) and inflammatory process. VitD regulates the expression of anti-inflammatory cytokines such as interleukin 10 (IL-10) and IL-6^\[[@r11]\]^. Two of the above-mentioned mechanisms are thought to be responsible for the high risk of AF in patients with vitD deficiency. In the current literature, there are inconsistent results about the association between vitD and risk of AF^\[[@r12],[@r13]\]^.

In light of this knowledge, we aimed to evaluate the association between serum vitD level and risk of AF recurrence after electrical or medical CV.

METHODS
=======

Study Population
----------------

Between September 2017 and October 2018, 52 retrospective patients were included in our study, admitted to our cardiology department with AF and rhythm control strategy, chosen for medical or electrical CV. Patients with thrombus in left atrial appendage or other cardiac chambers, severe mitral valve disease, obstructive sleep apnea syndrome, hyperthyroidism, acute coronary syndrome, and using any medication that could affect vitD levels were excluded from the study. Patients with permanent AF were also excluded. Transesophageal echocardiography (TEE) was performed in all patients before CV, regardless of taking anticoagulant treatment and AF duration. After a successful CV, patients were followed for six months with regard to AF recurrence. The study was approved by the local Ethics Committee, and all patients provided written informed consent.

A detailed medical history of each patient was compiled, including the history of DM, HT, hyperlipidemia, peripheral artery disease, smoking, alcohol use, family history of CAD and treatment history. The patients' height and weight in fasting were measured; body mass indexes (BMI) (weight/height in kg/m^2^) were calculated. Fasting plasma glucose, total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, thyroid-stimulating hormone (TSH) and serum vitD levels were assayed in blood samples after 12 hours overnight fasting before CV.

Echocardiographic Examination
-----------------------------

The two-dimensional (2D) transthoracic echocardiography and TEE were performed to all participants before CV with available system (Vivid E9 system; General Electric Healthcare, Milwaukee, Wisconsin, USA). Standard 2D echocardiographic measurements were taken according to the guidelines of the American Society of Echocardiography and the European Society of Echocardiography^\[[@r14]\]^. Spontaneous echo contrast left atrial appendage thrombus and pulse wave velocities of left atrial appendage were evaluated by TEE.

Definition of AF
----------------

Paroxysmal atrial fibrillation (PAF) is defined as an episode of AF, which ends with electrical or medical CV in less than seven days. Persistent AF is defined as an AF, which occurs longer than seven days and ends with CV^\[[@r13]\]^. Routine electrocardiography (ECG) was performed at each visit, and 24-hour ECG Holter monitoring was scheduled for the 6-month follow-up visit. AF recurrence is defined as an AF pattern in 12-lead ECG recording after CV within 6 months or lasting more than 30 seconds of AF attacks in ECG Holter recording at 6 months of follow-up.

Cardioversion
-------------

Medical CV was preferred with amiodarone first with the regimen following the 300 mg intravenous (IV) bolus over 30 to 60 minutes, 1000 mg continuous IV infusion regimen up to 24 hours. The electrical CV was performed to non-responders of medical CV. Electrical CV was performed with patients in a fasting state under sedation and biphasic cardioverter-defibrillator devices between 50-200 Joules in synchronised mode. In patients with normal or low body mass index, the first shocks were done with 100 Joules, and, if the first shock is unsuccessful, the energy was increased. Also, in obese or over-weight patients, a higher energy shock was selected. To maintain sinus rhythm, amiodarone was added to treatment with 200 mg twice dayly after successful CV until hospital discharge.

Statistical Analysis
--------------------

Data were analysed using SPSS software version 17.0 (SPSS, Chicago, IL, USA). Quantitative data were presented as mean ± standard deviation. The Shapiro-Wilk test was used to test continuous variables for normality distribution. Student\'s t-test was used to evaluate continuous variables showing the normal distribution and Mann-Whitney U-test was used to evaluate variables that did not show normal distribution. Categorical variables were expressed as percentages. Chi-square test was used to compare categorical variables. Associations between serum vitamin D, AF recurrence, and other clinical parameters with regard to AF status were examined by univariable and multivariable logistic regression. A multivariable logistic regression model was used to derive odds ratio (OR) for the risk of AF, so that each potential confounder variable with a *P*-value ≤ 0.10 (based on univariable analysis) was entered. Statistical significance was defined as a *P*-value \< 0.05.

RESULTS
=======

Fifty-two patients met the inclusion criteria and were included in the study; one patient was excluded due to lacking of laboratory data. Baseline characteristics of the randomised patients are listed in [Table 1](#t1){ref-type="table"}. There were 51 patients, with a mean age of 69.7 years, and 39.2% of them were female. Electrical CV was performed in 84.3% of the patients. After CV, the mean duration of the follow-up period was 6±2 months. In our study, AF recurrence after CV was 58.8% (n=30).

###### 

Demographic features.

  Clinical parameters            Mean±SD
  ------------------------------ -------------
      Age (years)                69.6±7.8
      Females, n (%)             20 (39.2)
      HT, n (%)                  26 (51)
      DM, n (%)                  10 (19.6)
      Smoking, n (%)             5 (9.8)
      Hyperlipidemia, n (%)      6 (11.8)
      CAD, n (%)                 22 (43.1)
      PAF, n (%)                 43 (84.3)
      CV (electrical), n (%)     43 (84.3)
      Recurrence, n (%)          30 (58.8)
      VitD replacement, n (%)    6 (11.8)
  Echocardiographic parameters    
      LA diameter (cm)           4.36±0.5
      LVH, n (%)                 10 (19.6)
  Laboratory parameters           
      Serum creatinine (mg/dl)   0.92±0.2
      TC (mg/dl)                 172.4±48.5
      LDL-C (mg/dl)              104.3±38.6
      HDL-C (mg/d)               41.9±10.9
      TG (mg/dl)                 127.2±60.6
      Calcium (mg/dl)            8.9±0.4
      TSH (mIU/ml)               1.5±0.8
      Vitamin B12 (pg/ml)        468.3±307.8
      25 (OH) VitD (ng/ml)       21.4±9.0

CAD=coronary artery disease; CV=cardioversion; DM=diabetes mellitus; HDL-C=high-density lipoprotein cholesterol; HT=hypertension; LA=left atrium; LDL-C=low-density lipoprotein cholesterol; LVH=left ventricular hypertrophy; PAF=paroxysmal atrial fibrillation; TC=total cholesterol; TG=triglyceride; TSH=thyroid-stimulating hormone; VitD=vitamin D

Baseline clinical, echocardiographic and laboratory parameters were compared in AF recurrence group and non-recurrence group in [Table 2](#t2){ref-type="table"}. The comparison of AF recurrence according to serum vitD level, left atrial size and age were shown in [Figure 1](#f1){ref-type="fig"}. Also, there is a negative correlation between vitD level and left atrial diameter in [Figure 2](#f2){ref-type="fig"} (*P*=0.006, r = -0.376).

###### 

Comparison of baseline demographic features in AF recurrence or non-recurrence groups.

  -----------------------------------------------------------------------------
                                    Recurrence\   Non-recurrence\   *P*-value
                                    (n=30)        (n=21)            
  --------------------------------- ------------- ----------------- -----------
  Age (years)                       71.1          67.4              0.107

  Females, n (%)                    13 (43.3)     7 (33.3)          0.472

  HT, n (%)                         15 (50)       11 (52.4)         0.867

  DM, n (%)                         4 (13.3)       6 (28.6)         0.177

  Smoking, n (%)                    3 (10)        2 (9.5)           0.955

  Hyperlipidemia, n (%)             4 (13.3)      2 (9.5)           0.678

  CAD, n (%)                        12 (40)       10 (47.6)         0.589

  PAF, n (%)                        26 (86.7)     17 (81)           0.581

  Electrical cardioversion, n (%)   23 (76.7)     20 (95.2)         0.073

  LVH, n (%)                        5 (16.7)      5 (23.8)          0.527

  LA diameter (cm)                  4.4           4.1                0.025

  Serum creatinine (mg/dl)          0.8           0.9               0.139

  TC (mg/dl)                        171.9         173.2             0.929

  LDL-C (mg/dl)                     104.7         103.7             0.929

  HDL-C (mg/dl)                     40.4          44.1              0.322

  TG (mg/dl)                        128           126.9             0.950

  Calcium (mg/dl)                   8.8           9.1               0.114

  TSH (mIU/ml)                      1.6           1.3               0.328

  Vitamin B12 (pg/ml)               456.9         485.5             0.764

  25 (OH) VitD (ng/ml)              18            26.3               0.001
  -----------------------------------------------------------------------------

CAD=coronary artery disease; DM=diabetes mellitus; HDL-C=high-density lipoprotein cholesterol; HT=hypertension; LA=left atrium; LDL-C=low-density lipoprotein cholesterol; LVH=left ventricular hypertrophy; PAF=paroxysmal atrial fibrillation; TC=total cholesterol; TG=triglyceride; TSH=thyroid-stimulating hormone; VitD=vitamin D.

Fig. 1The box-plot graph shows the comparison of atrial fibrillation recurrence according to serum 25 (OH) VitD level (A), left atrium size (B), and age (C). \* P\<0.05, \*\* P\<0.01.

Fig. 2Correlation analysis shows a signficantly negative correlation between left atrial diameter and 25 (OH) VitD level.

Left atrial diameter was larger in AF recurrence group when compared to the non-recurrence group (4.4 cm *vs*. 4.1 cm, *P*=0.025). Patients with AF recurrence were older, and HT was frequently seen in the AF recurrence group; however, there was no statistically significant difference (*P*=0.107, *P*=0.867, respectively). The prevalence of PAF was 84.3% (n=43), persistent AF was 15.7% (n=8) in our study, and AF recurrence was similar between the two groups (*P*=0.581). In addition, when comparing CV modalities, the prevalence of AF recurrence was higher in electrical CV group than in medical CV group; however, there was no statistically significant difference (*P*=0.073). Comparison of baseline demographic features in electrical CV and medical CV groups was shown in [Table 3](#t3){ref-type="table"}.

###### 

Comparison of baseline demographic features in the electrical CV and medical CV groups.

  ---------------------------------------------------------------------
                             Electrical CV\   Medical CV\   *P*-value
                             (n=43)           (n=8)         
  -------------------------- ---------------- ------------- -----------
  Age (years)                69.3             71.2          0.635

  Female gender, n (%)       14 (32.6)        6 (75)        0.024

  HT, n (%)                  23 (53.5)        3 (37.5)      0.406

  DM, n (%)                  8 (18.6)         2 (25)        0.676

  Smoking, n (%)             4 (9.3)          1 (12.5)      0.780

  Hyperlipidemia, n (%)      5 (11.6)         1 (12.5)      0.944

  CAD, n (%)                 21 (48.8)        1 (12.5)      0.057

  Paroxysmal AF, n (%)       36 (83.7)        7 (87.5)      0.787

  LVH, n (%)                 8 (18.6)         2 (25)        0.676

  LA diameter (cm)           4.3              4.4           0.606

  Serum creatinine (mg/dl)   0.9              0.7           0.058

  TC (mg/dl)                 170.1            182.6         0.414

  LDL-C (mg/dl)              104              105.6         0.726

  HDL-C (mg/dl)              40.3             48.7          0.498

  TG (mg/dl)                 124.4            141.1         0.515

  Calcium (mg/dl)            9.0              8.9           0.135

  TSH (mIU/ml)               1.4              1.9           0.934

  Vitamin B12 (pg/ml)        496.1            339.7         0.095

  25 (OH) VitD (ng/ml)       21.8             19.4          0.103

  AF recurrence n (%)        23 (53.5)        7 (87.5)      0.073
  ---------------------------------------------------------------------

AF=atrial fibrillation; CAD=coronary artery disease; CV=cardioversion; DM=diabetes mellitus; HDL-C=high density lipoprotein cholesterol; HT=hypertension; LA=left atrium; LDL-C=low density lipoprotein cholesterol; LVH=left ventricular hypertrophy; TC=total cholesterol; TG=triglyceride; TSH=thyroid-stimulating hormone; VitD=vitamin D

The mean vitD level was 21.4 ng/ml in our study population. The vitD level was lower in the AF recurrence group than the non-recurrence group (18 ng/ml *vs*. 26.3 ng/ml, *P*=0.001). Receiver operating characteristic curve was used to explore the relationship between vitD level, which was measured before CV and AF recurrence after CV. The area under the curve was 0.745. Using a cut-off level of \<22.0 ng/ml, the pre-CV vitD level was associated with prediction of AF recurrence after CV with a sensitivity of 76.2% and specificity of 67.7% ([Figure 3](#f3){ref-type="fig"}). Univariate and multivariate analysis of basal demographic features showed a correlation between vitD and AF recurrence after CV ([Table 4](#t4){ref-type="table"}).

Fig. 3The receiver operating characteristic curve represents the cut-off point of 25 (OH) VitD level in predicting AF recurrence after CV.

###### 

Univariate and multivariate analysis of baseline demographic features.

                             Univariate   Multivariate                           
  -------------------------- ------------ -------------- ------- ------- ------- -------
  Age (years)                --0.70       0.48           0.149                    
  LA diameter (cm)           --1.213      0.873          0.165                    
  Serum creatinine (mg/dl)   3.117        2.026          0.124                    
  25 (OH) VitD (ng/ml)       0.100        0.046          0.031   0.121   0.042   0.004

LA=left atrium; VitD=vitamin D

DISCUSSION
==========

In our study, lower serum vitD levels were found in the AF recurrence group, and vitD is an independent predictor of AF recurrence after CV. Another finding of our study is that the left atrial size was larger in the AF recurrence group.

VitD deficiency is known to play a key role in the pathogenesis of CAD, left ventricular hypertrophy and AF^\[[@r11],[@r15],[@r16]\]^. The vitD deficiency has been shown to be associated with left atrial fibrosis and increased risk of AF recurrence after ablation^\[[@r17]\]^. But this is the first study in the literature to evaluate the role of vitD deficiency in AF recurrence after CV.

The exact mechanisms of vitD deficiency in the cardiovascular system are not well-established. VitD has anti-oxidant and anti-inflammatory effects with regulating anti-inflammatory cytokines, including IL-10 and IL-6^\[[@r18],[@r19]\]^. Besides that regulating calcium metabolism, vitD has electromechanical effects in the left atrium^\[[@r20]\]^. The link between vitD deficiency and development of AF, CAD and HT is explained with the decrease of anti-inflammatory effects in cardiac myocytes. Structural, electrical and contractile functions play a role in AF development. Left atrial fibrosis is the main mechanism of structural remodelling which progresses to AF. The association between left atrial fibrosis and vitD was found in a previous study by Canpolat et al.^\[[@r17]\]^. Oxidative stress, inflammation, and RAAS activation are the main mechanisms responsible for atrial fibrosis and might be associated with AF recurrence after ablation in patients with vitD deficiency^\[[@r21]\]^. Additionally, preoperative vitD supplementation could prevent postoperative AF after coronary artery bypass surgery^\[[@r22]\]^.

CV is the main treatment modality in symptomatic AF patients. AF ablation is another treatment modality to maintain sinus rhythm. After CV and ablation, a large part of patients fails to maintain sinus rhythm at follow-up^\[[@r23]\]^. AF type is the most important factor in predicting AF recurrence, such as permanent AF, with a high risk of AF recurrence after ablation; however, patient characteristics such as age, sex, HT, smoking, and CAD were not associated with AF recurrence after AF ablation^\[[@r9]\]^. In our study, although HT and advanced age are associated with AF recurrence after CV, there was no statistically significant difference. Besides that, obstructive sleep disorder may cause AF recurrence after CV or ablation with several mechanisms, such as nocturnal hypoxemia and sympathetic nervous system activity, which can activate atrial stretching and diastolic dysfunction^\[[@r24]\]^. Patients with obstructive sleep apnea syndrome were excluded from our study.

Left atrial size was also shown to be an important factor in predicting AF recurrence. Patients with left atrial size greater than 4 cm have a higher AF recurrence risk^\[[@r25]\]^. In our study, the mean left atrial diameter was 4.4 cm in the recurrence group, which was significantly larger than in the non-recurrence group.

Limitations
-----------

Our study results should be evaluated as a part of several limitations; first, patients were taking different types of antiarrhythmic drugs; there was no homogenization in drug classes, which may affect the AF recurrence. Second, the duration between the first diagnosis of AF to CV is unknown in the paroxysmal AF group. Third, we did not take a blood sample for vitD and perform control echocardiography at six months of follow-up. The small sample size is another limitation of the study.

CONCLUSION
==========

Lower vitD levels are associated with increased risk of AF recurrence after CV. Due to the close association between vitD deficiency and increased risk of AF recurrence, considering vitD levels before CV might be beneficial for the maintenance of sinus rhythm, and the vitD replacement in patients with vitD deficiency may prevent AF recurrence after CV.
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